The role of negative hyperselection in metastatic colorectal cancer.
作者信息
Ji Jingran, Fakih Marwan
机构信息
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
出版信息
J Gastrointest Oncol. 2024 Oct 31;15(5):2353-2357. doi: 10.21037/jgo-24-376. Epub 2024 Oct 16.
Abstract
摘要
相似文献
1
The role of negative hyperselection in metastatic colorectal cancer.阴性超选择在转移性结直肠癌中的作用。
J Gastrointest Oncol. 2024 Oct 31;15(5):2353-2357. doi: 10.21037/jgo-24-376. Epub 2024 Oct 16.
2
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).帕尼单抗维持治疗RAS野生型转移性结直肠癌中耐药突变的阴性超选择（帕尼单抗维持治疗转移性结直肠癌II期试验，AIO KRK 0212）
Clin Cancer Res. 2024 Apr 1;30(7):1256-1263. doi: 10.1158/1078-0432.CCR-23-3023.
3
KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.KRAS p.G13D 突变与结直肠癌细胞系对抗 EGFR 抗体治疗的敏感性相关。
J Cancer Res Clin Oncol. 2013 Feb;139(2):201-9. doi: 10.1007/s00432-012-1319-7. Epub 2012 Sep 27.
4
Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months.帕尼单抗为贝伐珠单抗治疗 6 个月内的转移性结直肠癌患者提供了优于西妥昔单抗的生存获益。
Oncology. 2019;96(3):132-139. doi: 10.1159/000493321. Epub 2018 Oct 25.
5
The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.西妥昔单抗（技术评估报告第176号综述）和帕尼单抗（技术评估报告第240号部分综述）用于既往未治疗的转移性结直肠癌的临床疗效和成本效果：一项系统评价与经济学评估
Health Technol Assess. 2017 Jun;21(38):1-294. doi: 10.3310/hta21380.
6
Negative hyperselection beyond RAS: is a key tool for choosing the optimal maintenance treatment in metastatic colorectal cancer?RAS基因以外的阴性超选择：是转移性结直肠癌选择最佳维持治疗的关键工具吗？
J Gastrointest Oncol. 2024 Oct 31;15(5):2349-2352. doi: 10.21037/jgo-24-284. Epub 2024 Oct 29.
7
The prognostic role of HIF-1α and NF-κB expression in RAS wild-type metastatic colorectal cancer: A Turkish Oncology Group (TOG) study.缺氧诱导因子-1α（HIF-1α）和核因子-κB（NF-κB）表达在 RAS 野生型转移性结直肠癌中的预后作用：土耳其肿瘤学组（TOG）研究。
J Cancer Res Clin Oncol. 2023 Aug;149(10):6849-6856. doi: 10.1007/s00432-023-04628-y. Epub 2023 Feb 20.
8
Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution.西妥昔单抗治疗后转移性结直肠癌进展时帕尼单抗治疗的安全性和有效性：日本一家机构的经验
Oncol Lett. 2013 Apr;5(4):1331-1334. doi: 10.3892/ol.2013.1171. Epub 2013 Feb 1.
9
Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience.帕尼单抗用于西妥昔单抗治疗后的安全性和有效性：纪念斯隆-凯特琳癌症中心经验回顾性研究。
Invest New Drugs. 2010 Jun;28(3):353-60. doi: 10.1007/s10637-009-9268-y. Epub 2009 May 26.
10
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.西妥昔单抗（单药或联合化疗）、贝伐珠单抗（联合非奥沙利铂化疗）和帕尼单抗（单药治疗）用于一线化疗后转移性结直肠癌治疗的临床疗效和成本效果评价（技术评估 150 号报告的部分回顾和技术评估 118 号报告的综述）：系统评价和经济模型。
Health Technol Assess. 2013 Apr;17(14):1-237. doi: 10.3310/hta17140.
本文引用的文献
1
Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).帕尼单抗维持治疗RAS野生型转移性结直肠癌中耐药突变的阴性超选择（帕尼单抗维持治疗转移性结直肠癌II期试验，AIO KRK 0212）
Clin Cancer Res. 2024 Apr 1;30(7):1256-1263. doi: 10.1158/1078-0432.CCR-23-3023.
2
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.初始接受帕尼单抗联合 FOLFOX 或 5-FU/LV 治疗的 RAS 和 BRAF 野生型转移性结直肠癌老年患者的负性选择。
Eur J Cancer. 2023 Dec;195:113396. doi: 10.1016/j.ejca.2023.113396. Epub 2023 Oct 20.
3
Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes.抗 EGFR 治疗对 HER2 阳性转移性结直肠癌的影响：临床结局的系统文献回顾和荟萃分析。
Oncologist. 2023 Oct 3;28(10):885-893. doi: 10.1093/oncolo/oyad200.
4
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.在RAS野生型转移性结直肠癌患者中，原发肿瘤部位作为治疗选择的驱动因素：一项随机试验的系统评价和汇总分析
Eur J Cancer. 2023 May;184:106-116. doi: 10.1016/j.ejca.2023.02.006. Epub 2023 Feb 17.
5
Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer.黏液组织学与左半侧 RAS/BRAF 野生型转移性结直肠癌患者对抗 EGFR 治疗的耐药性相关。
Oncologist. 2022 Mar 4;27(2):104-109. doi: 10.1093/oncolo/oyab028.
6
Negative Ultraselection of Patients With / Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti-EGFR-Based Therapy.抗 EGFR 治疗的野生型、微卫星稳定转移性结直肠癌患者的负超选择。
JCO Precis Oncol. 2022 Apr;6:e2200037. doi: 10.1200/PO.22.00037.
7
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.转移性结直肠癌中抗 EGFR 治疗的耐药性：潜在机制与逆转策略。
J Exp Clin Cancer Res. 2021 Oct 18;40(1):328. doi: 10.1186/s13046-021-02130-2.
8
Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212).帕尼单抗联合氟尿嘧啶和亚叶酸治疗与氟尿嘧啶和亚叶酸单独维持治疗野生型转移性结直肠癌：PANAMA 试验（AIO KRK 0212）的随机研究。
J Clin Oncol. 2022 Jan 1;40(1):72-82. doi: 10.1200/JCO.21.01332. Epub 2021 Sep 17.
9
Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.原发肿瘤侧别对未经治疗的晚期结直肠癌预后和预测的影响。
J Natl Cancer Inst. 2021 Nov 29;113(12):1705-1713. doi: 10.1093/jnci/djab112.
10
Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.伴有 和 野生型转移性结直肠癌患者接受帕尼单抗维持治疗的负性选择。
J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.
Zotero 插件